Research Progress of PRMT5 in Gynecological Malignant Tumors
SONG Meng-meng
CHEN Fang
BAO Xiang-xiang
TIAN Xin-li
Abstract：Protein arginine methyltransferase 5(PRMT5),a major member of the PRMT family,catalyzes the methylation of arginine residues in both histone and non-histone proteins.PRMT5 is involved in many biological processes such as transcription,RNA splicing,DNA repair,and cell cycle control.Current studies have shown that PRMT5 is closely related to the occurrence and development of human malignant tumors and plays a similar role as an oncogene.Ovarian cancer,cervical cancer and endometrial cancer,as the three major gynecological malignancies,pose a serious threat to women's life and health.The up-regulated PRMT5 in ovarian cancer,cervical cancer and endometrial cancer can promote the clonal formation,DNA replication and proliferation of tumor cells.By regulating the tumor cell migration in an EMT-dependent manner,PRMT5 can enhance the stability and expression of programmed death ligand-1(PD-L1)on cervical cancer cells,thus promoting tumor immune escape.In addition,PRMT5 inhibitor combined with epigenetic drugs can promote tumor cell senescence,enhance the chemotherapy sensitivity of ovarian cancer cells to docetaxel,cooperate with poly(ADP-ribose)polymeras(PARP)inhibitors to inhibit the growth and proliferation of ovarian cancer cells,and reduce the adverse reactions caused by PARP inhibitors,suggesting that PRMT5 inhibitor can be used for maintenance treatment of ovarian cancer.It is expected to provide new ideas for the treatment and prognosis of gynecological malignant tumors.
Keywords：Protein-arginine N-methyltransferasesUterine cervical neoplasmsOvarian neoplasmsEndometrial neoplasmsEpithelial-mesenchymal transition
Publication Date：2025-03-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 171-176 )